Shares in Prosensa Holding NV plunged 70.3 percent last Friday on news that its exon-skipping antisense drug drisapersen failed to meet the primary endpoint of a Phase III trial in Duchenne muscular dystrophy (DMD). Read More
LONDON – A protein that has a role in causing the most frequent form of inherited mental retardation has turned out to be a master regulator of a large group of molecules involved in cancer progression and metastasis. Read More
Morphosys AG raised €84 million (US$114 million) in a private placement, adding another hefty chunk of change to what is already a robust balance sheet. Read More
SHANGHAI – Two Chinese biopharmaceutical firms have been added to an ongoing corruption probe in China that has already expanded to cover several multinationals. Read More
LONDON – Two years after halting development of bovine alkaline phosphatase, AM-Pharma is back in the clinic with its new recombinant human version of the anti-inflammatory enzyme. Read More
A consortium led by the Royal College of Surgeons in Ireland (RCSI) has secured €11.5 million (US$15.4 million) in funding from the European Commission (EC) to build a comprehensive picture of microRNA (miRNA) biology in patients with epilepsy. Read More
SHANGHAI – Beijing newcomer Canbridge Life Sciences Ltd. has partnered with emerging nanotech specialist Azaya Therapeutics Inc., of San Antonio, to develop non-small-cell lung cancer (NSCLC) treatment ATI-1123 in China and North Asia. Read More
• Ipsen SA, of Paris, reported positive top-line findings from the primary endpoint of the ELECT study assessing the effect of Somatuline Autogel/Somatuline Depot (lanreotide) Injection 120 mg in controlling symptoms in patients with neuroendocrine tumors associated with carcinoid syndrome. Read More
